Cassava Sciences Inc (NASDAQ:SAVA) is facing controversy as a recent investigation by the City University of New York (CUNY) has implicated neuroscientist Hoau-Yan Wang, a long-time collaborator of Cassava, in scientific misconduct related to 20 research papers. These papers were crucial in advancing simufilam, the company's lead Alzheimer's program. The investigation could not definitively prove its suspicions as Dr. Wang did not provide the original raw data. Last year, the U.S. Justice Department opened a criminal investigation into Cassava Sciences on whether it manipulated research results for its investigational Alzheimer's drug.